LinsemanDAHamptomLABranstetterDG. Quinolone-induced arthropathy in the neonatal mouse: morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol. 1995;28:59-64.
2.
KatoMOnoderaT. Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol. 1988;11:110-119.
3.
GoughABarsoumNJMitchellLMcGuireEJdelaIglesiaFA. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51:177-187.
4.
MachidaMKusajimaHAijimaHMaedaAIshidaRUchidaH. Toxicokinetic study of norfloxacin-induced arthroplasty in juvenile animals. Toxicol Appl Pharmacol. 1990;105:403-412.
5.
BendeleAMHulmanFHarveyAKHrubeyPSChandrasekhaS. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol Pathol. 1990;18:304-312.
6.
EwingPJNessDK. Quinolone arthropathy in juvenile ferrets. Vet Pathol. 1995;32:599.
7.
von KeutzERuhl-FehlertCDrommerWRosenbruchM. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004;78:418-424.
8.
BurkhartJEWalterspielJNSchaadUB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.
9.
VormanJForsterCZippelU. Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcif Tissue Int. 1997;61:230-238.
10.
WilliamsRJAttiaEWickiewiczTLHannafinJA. The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med. 2000;28:364-369.
11.
Saez-LlorensXMcCoigCFerisJM. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J. 2002;21:14-21.
12.
PichicheroMEArguedasADaganR. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis. 2005;41:470-478.
BradleyJSJacksonMA. The use of systemic and topical fluoroquinolones. Am Acad Pediatr. 2011;128:e1034-e1045.
15.
NoelGJBradleyJSKauffmanRE. Comparative safety profile of levofloxacin in 2523 children with a focus of four musculoskeletal disorders. Pediatr Infect Dis J. 2007;26:879-891.
16.
BradleyJSKauffmanREBalisDA. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Am Acad Pediatr. 2014;134:e146-153.
